116 related articles for article (PubMed ID: 23063549)
1. Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor.
Adulnirath A; Chung SW; Park J; Hwang SR; Kim JY; Yang VC; Kim SY; Moon HT; Byun Y
J Control Release; 2012 Nov; 164(1):8-16. PubMed ID: 23063549
[TBL] [Abstract][Full Text] [Related]
2. An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties.
Bae SM; Kim JH; Chung SW; Byun Y; Kim SY; Lee BH; Kim IS; Park RW
Biomaterials; 2013 Mar; 34(8):2077-86. PubMed ID: 23245333
[TBL] [Abstract][Full Text] [Related]
3. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor.
Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY
Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020
[TBL] [Abstract][Full Text] [Related]
4. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
[TBL] [Abstract][Full Text] [Related]
5. Oral delivery of a potent anti-angiogenic heparin conjugate by chemical conjugation and physical complexation using deoxycholic acid.
Alam F; Al-Hilal TA; Chung SW; Seo D; Mahmud F; Kim HS; Kim SY; Byun Y
Biomaterials; 2014 Aug; 35(24):6543-52. PubMed ID: 24816287
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Anti-Angiogenic Effect of Low Molecular Weight Heparin-Bile Acid Conjugates by Co-Administration of a Selective COX-2 Inhibitor.
Kim JY; Chung SW; Kim SY; Byun Y
Pharm Res; 2015 Jul; 32(7):2318-27. PubMed ID: 25585956
[TBL] [Abstract][Full Text] [Related]
7. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y
J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701
[TBL] [Abstract][Full Text] [Related]
8. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
9. Potentiation of anti-angiogenic activity of heparin by blocking the ATIII-interacting pentasaccharide unit and increasing net anionic charge.
Chung SW; Lee M; Bae SM; Park J; Jeon OC; Lee HS; Choe H; Kim HS; Lee BS; Park RW; Kim SY; Byun Y
Biomaterials; 2012 Dec; 33(35):9070-9. PubMed ID: 23010574
[TBL] [Abstract][Full Text] [Related]
10. Reduced graphene oxide nanosheets coated with an anti-angiogenic anticancer low-molecular-weight heparin derivative for delivery of anticancer drugs.
Shim G; Kim JY; Han J; Chung SW; Lee S; Byun Y; Oh YK
J Control Release; 2014 Sep; 189():80-9. PubMed ID: 24973719
[TBL] [Abstract][Full Text] [Related]
11. Preliminary safety evaluation of a taurocholate-conjugated low-molecular-weight heparin derivative (LHT7): a potent angiogenesis inhibitor.
Alam F; Chung SW; Hwang SR; Kim JY; Park J; Moon HT; Byun Y
J Appl Toxicol; 2015 Jan; 35(1):104-15. PubMed ID: 24532548
[TBL] [Abstract][Full Text] [Related]
12. Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models.
Alam F; Hwang SR; Al-Hilal TA; Chung SW; Kim HS; Kang BH; Zhang HS; Shin SH; Lee JY; Kang MS; Kwon GH; Jeon OC; Kim SY; Byun Y
Drug Dev Ind Pharm; 2016 Aug; 42(8):1247-57. PubMed ID: 26612099
[TBL] [Abstract][Full Text] [Related]
13. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Topical Low-Molecular-Weight Heparin-Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization.
Moon CH; Moon BG; Kim JY; Kim MJ; Tchah H
Cornea; 2017 Apr; 36(4):497-501. PubMed ID: 27941385
[TBL] [Abstract][Full Text] [Related]
15. Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex.
Kim JY; Shim G; Choi HW; Park J; Chung SW; Kim S; Kim K; Kwon IC; Kim CW; Kim SY; Yang VC; Oh YK; Byun Y
Biomaterials; 2012 Jun; 33(17):4424-30. PubMed ID: 22425551
[TBL] [Abstract][Full Text] [Related]
16. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
17. Integrin αvβ3-targeted dynamic contrast-enhanced magnetic resonance imaging using a gadolinium-loaded polyethylene gycol-dendrimer-cyclic RGD conjugate to evaluate tumor angiogenesis and to assess early antiangiogenic treatment response in a mouse xenograft tumor model.
Chen WT; Shih TT; Chen RC; Tu SY; Hsieh WY; Yang PC
Mol Imaging; 2012; 11(4):286-300. PubMed ID: 22954145
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. In vivo optical imaging of integrin alphaV-beta3 in mice using multivalent or monovalent cRGD targeting vectors.
Jin ZH; Josserand V; Foillard S; Boturyn D; Dumy P; Favrot MC; Coll JL
Mol Cancer; 2007 Jun; 6():41. PubMed ID: 17565663
[TBL] [Abstract][Full Text] [Related]
20. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
Reinmuth N; Liu W; Ahmad SA; Fan F; Stoeltzing O; Parikh AA; Bucana CD; Gallick GE; Nickols MA; Westlin WF; Ellis LM
Cancer Res; 2003 May; 63(9):2079-87. PubMed ID: 12727823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
